These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11479542)

  • 1. Fickle financing climate continues.
    Mitchell P
    Nat Biotechnol; 2001 Aug; 19(8):695-6. PubMed ID: 11479542
    [No Abstract]   [Full Text] [Related]  

  • 2. Financing bonanza set to continue.
    Davidson S
    Nat Biotechnol; 2000 Sep; 18(9):922-3. PubMed ID: 10973203
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotechnology venture capital booms in Japan.
    Saegusa A
    Nat Biotechnol; 2000 Mar; 18(3):256. PubMed ID: 10700128
    [No Abstract]   [Full Text] [Related]  

  • 4. Putting a price on biotechnology.
    Stewart JJ; Allison PN; Johnson RS
    Nat Biotechnol; 2001 Sep; 19(9):813-7. PubMed ID: 11533634
    [No Abstract]   [Full Text] [Related]  

  • 5. Biotech sector ponders potential 'bloodbath'.
    Mitchell P
    Nat Biotechnol; 2009 Jan; 27(1):3-4. PubMed ID: 19131974
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotech marks time in Q3.
    Lawrence S
    Nat Biotechnol; 2005 Nov; 23(11):1332. PubMed ID: 16273049
    [No Abstract]   [Full Text] [Related]  

  • 7. Upward trend in financing continues, but fewer feel flush.
    Lawrence S
    Nat Biotechnol; 2007 Jan; 25(1):3. PubMed ID: 17211374
    [No Abstract]   [Full Text] [Related]  

  • 8. Looking at US versus European exit opportunities.
    Lawrence S
    Nat Biotechnol; 2005 Oct; 23(10):1203. PubMed ID: 16302294
    [No Abstract]   [Full Text] [Related]  

  • 9. This means war.
    Nat Biotechnol; 2008 Sep; 26(9):954. PubMed ID: 18779784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The changing attitude of European VCs.
    Mitchell P
    Nat Biotechnol; 2004 Apr; 22(4):479. PubMed ID: 15085807
    [No Abstract]   [Full Text] [Related]  

  • 11. Public markets show signs of life.
    Mitchell P
    Nat Biotechnol; 2003 Aug; 21(8):833-4. PubMed ID: 12894181
    [No Abstract]   [Full Text] [Related]  

  • 12. Partnering up in Q3.
    Lawrence S
    Nat Biotechnol; 2007 Nov; 25(11):1200. PubMed ID: 17989659
    [No Abstract]   [Full Text] [Related]  

  • 13. The rise of venture capital and biotechnology in the US and Europe.
    Lee DP; Dibner MD
    Nat Biotechnol; 2005 Jun; 23(6):672-6. PubMed ID: 15940233
    [No Abstract]   [Full Text] [Related]  

  • 14. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 15. The rise of European venture capital for biotechnology.
    Howell M; Trull M; Dibner MD
    Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
    [No Abstract]   [Full Text] [Related]  

  • 16. Mixed results in Q1.
    Lawrence S
    Nat Biotechnol; 2005 May; 23(5):518. PubMed ID: 15877059
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotechnology financing dilemmas and the role of special purpose entities.
    Schiff L; Murray F
    Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945
    [No Abstract]   [Full Text] [Related]  

  • 18. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 19. Life support for life science innovation?
    Nat Biotechnol; 2007 Feb; 25(2):144. PubMed ID: 17287731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are small biotechs still underselling themselves?
    Ransom J
    Nat Biotechnol; 2006 May; 24(5):477. PubMed ID: 16680112
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.